Ebola Outbreak 2026: DRC and Uganda Battle Fastest Growing Bundibugyo Epidemic on Record

The 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo and Uganda has become the deadliest and fastest-growing Ebola epidemic caused by this rare viral strain, with 598 confirmed cases and 115 deaths recorded as of June 8, 2026. The World Health Organization has declared a Public Health Emergency of International Concern, and global health authorities are racing to contain the spread.

What Is the Bundibugyo Virus?

Bundibugyo virus is one of four known Orthoebolavirus species capable of causing severe disease in humans. First identified in Uganda in 2007, it belongs to the same family as the more widely known Zaire ebolavirus but has distinct characteristics that make it particularly challenging to manage.

Unlike the Zaire strain, there are currently no approved vaccines or specific antiviral treatments for Bundibugyo virus disease. This means containment relies entirely on traditional public health measures: rapid case identification, isolation, contact tracing, safe burials, and community engagement.

In previous outbreaks, BVD carried a case fatality rate of 30 to 50 percent. The current outbreak has a lower CFR of approximately 19 percent, which WHO attributes to improved clinical care protocols and earlier treatment interventions.

Outbreak at a Glance: Numbers That Demand Attention

As of the latest data from the European Centre for Disease Prevention and Control and WHO:

• 598 confirmed cases in the Democratic Republic of the Congo, plus 19 confirmed cases in Uganda
• 115 deaths among confirmed cases, with an additional probable death in Uganda
• 297 people currently hospitalized in isolation
• 16 healthcare workers infected in the DRC alone
• Cases reported across 25 health zones in three provinces

The outbreak epicenter is the Mongbwalu Health Zone in Ituri Province, a mining region with high population movement. Ituri accounts for 94 percent of all confirmed cases.

Cross-Border Spread and Global Concern

The outbreak has already crossed into Uganda, where 19 confirmed cases and two deaths have been reported. All Ugandan cases can be traced to travelers arriving from the DRC, and there has been no documented community transmission within Uganda. However, the situation remains volatile.

Of serious concern, one infected individual traveled from the DRC through Uganda to the United Arab Emirates and back before being identified. WHO is working with UAE authorities, who rapidly implemented risk assessment and contact tracing, and have found no evidence of onward spread. This incident underscores how quickly this virus can cross borders in our interconnected world.

Why This Outbreak Is Different

Several factors make this the most dangerous Bundibugyo outbreak ever recorded:

Unprecedented speed and scale. This outbreak has grown faster than any previous Bundibugyo event. The case count has accelerated rapidly since the outbreak was declared in May, and the geographic spread across three provinces demonstrates how difficult containment has become.

No approved vaccine. The rVSV-ZEBOV vaccine, which is effective against the Zaire ebolavirus, provides little to no cross-protection against Bundibugyo. WHO has recommended against its use for this outbreak. Discussions are underway to fast-track clinical trials for new vaccine candidates.

Conflict and insecurity. The outbreak is unfolding in a region affected by ongoing conflict, including M23 rebel activity in North Kivu. Security-related incidents affecting health facilities have constrained response operations, disrupted surveillance, and increased the risk of undetected transmission.

Mining and population movement. Ituri Province is a major artisanal mining zone with constant population movement, making contact tracing exceptionally difficult. As of June 8, contact tracing was running at only 45 percent — far below the 90 percent threshold needed to stay ahead of an outbreak.

Global Response and Funding

The international community has mobilized a substantial but still insufficient response:

• The U.S. has pledged over $220 million in direct Ebola response funding
• WHO and Africa CDC launched a joint continental preparedness plan with a $518 million funding ask
• The response still faces a $115 million funding gap
• The European Union pledged €15 million for Ebola response and preparedness
• MSF is building a 65-bed Ebola treatment center in Ituri

Kenya, Rwanda, Burundi, and South Sudan are all considered at-risk for importation and are enhancing their preparedness measures.

Risk Assessment for Travelers

The CDC continues to assess the risk to the general U.S. public as low. Ebola viruses do not spread through the air or through casual contact. Transmission requires direct contact with the bodily fluids of an infected person or contaminated surfaces.

However, enhanced screening measures are in place. Since May 18, travelers arriving from DRC and Uganda have been routed through four designated U.S. airports — Dulles, Atlanta Hartsfield-Jackson, Houston George Bush Intercontinental, and JFK — for Ebola screening and health monitoring.

Travel advisory: The CDC urges against non-essential travel to affected areas of DRC and Uganda. Anyone who has visited these regions and develops fever, body aches, vomiting, diarrhea, or unexplained bleeding within 21 days of return should contact a healthcare provider immediately — by phone before arriving in person — and disclose their travel history.

What Makes Bundibugyo Virus Hard to Detect?

Early symptoms are frustratingly non-specific. Fever, fatigue, muscle pain, headache, and sore throat mimic malaria, typhoid, and many other common illnesses common in the region. Without laboratory confirmation using PCR testing, clinicians cannot differentiate BVD from these endemic conditions.

This diagnostic challenge is amplified by the fact that three laboratories in DRC have reportedly run out of testing supplies — a critical gap that WHO has flagged as urgently needing resolution.

The incubation period ranges from 2 to 21 days, and individuals are not infectious until symptoms appear. This window means travelers can unknowingly carry the virus across borders.

Frequently Asked Questions About the 2026 Ebola Outbreak

How many Ebola cases are there right now?

As of June 8, 2026, there are 598 confirmed cases in the DRC and 19 in Uganda, with a combined total of 115 confirmed deaths. These numbers are rising rapidly.

Is there a risk of a global pandemic?

The WHO and CDC assess the global risk as moderate. While the outbreak is serious and growing, Ebola does not spread through the air. With adequate containment measures, including contact tracing and isolation, the virus can be controlled. The key concern is the current low contact tracing rate of 45 percent.

Can Bundibugyo virus be treated?

There are no approved specific treatments for BVD. Care is supportive, focusing on rehydration, oxygen therapy, and treatment of secondary infections. Clinical trials for potential treatments are under discussion.

Is there a vaccine available?

Not yet. The existing Ebola vaccines target the Zaire strain and are not effective against Bundibugyo. WHO is working to fast-track emergency clinical trials for new vaccine candidates.

Should I be worried if I’m traveling internationally?

If you are not traveling to the affected regions of DRC or Uganda, your risk is negligible. Enhanced airport screening is in place for travelers from affected countries. The CDC recommends avoiding non-essential travel to outbreak areas.

What is the U.S. doing to respond?

The U.S. has committed over $220 million in direct response funding and $350 million in broader humanitarian assistance. The CDC has implemented enhanced screening at four major airports. A quarantine facility plan in Kenya has faced legal challenges and protests.

Looking Ahead

The next few weeks will be critical. The WHO has warned that without a significant scale-up in response capacity — particularly in contact tracing, laboratory testing, and community engagement — this outbreak could continue to expand across borders. The joint Africa CDC-WHO continental response plan is designed to stop the outbreak where it is, support affected countries, and ensure neighboring nations are prepared.

For healthcare professionals, this outbreak is a stark reminder of the importance of robust infection prevention and control measures, especially in settings where viral hemorrhagic fevers may present with non-specific symptoms. Taking a thorough travel history has never been more important.

Health Professional Radio will continue to monitor this rapidly evolving situation and provide updates as more information becomes available.